Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
Latest Information Update: 16 Sep 2024
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms RELAZA2
- 08 Dec 2020 Status changed to completed as per results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology